Intelligence Feed event · Policy · 2026-10-19

    Zentalis Reports 15.8-Month Median OS in Cyclin E1-Positive Ovarian Cancer at ESMO

    Question

    Zentalis Reports 15.8-Month Median OS in Cyclin E1-Positive Ovarian Cancer at ESMO

    Direct answer

    Zentalis presented initial overall survival metrics from the DENALI Part 1b study evaluating its oral WEE1 kinase inhibitor azenosertib. The data was published in abstract format for the European Society for Medical Oncology Congress 2026. In platinum-resistant ovarian cancer patients expressing Cyclin E1 (n=48), median overall survival reached 15.8 months, compared to 7.5 months in negative cohorts. The biomarker stratification establishes clinical differentiation for registrational design.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Zentalis Reports 15.8-Month Median OS in Cyclin E1-Positive Ovarian Cancer at ESMO”, revision 1, evidence through 2026-10-19. https://marketontology.com/market-events/2026-10-19/zentalis-reports-15-8-month-median-os-in-cyclin-e1-positive-ovarian-cancer-at-es-67ae4f

    POLICY
    Zentalis Reports 15.8-Month Median OS in Cyclin E1-Positive Ovarian Cancer at ESMO
    Zentalis presented initial overall survival metrics from the DENALI Part 1b study evaluating its oral WEE1 kinase inhibitor azenosertib. The data was published in abstract format for the European Society for Medical Oncology Congress 2026. In platinum-resistant ovarian cancer patients expressing Cyclin E1 (n=48), median overall survival reached 15.8 months, compared to 7.5 months in negative cohorts. The biomarker stratification establishes clinical differentiation for registrational design.
    ZNTL
    Impact
    70
    OCT 19
    SIG
    85%
    ZNTL
    Zentalis Reports 15.8-Month Median OS in Cyclin E1-Positive Ovarian Cancer at ESMO
    Zentalis presented initial overall survival metrics from the DENALI Part 1b study evaluating its oral WEE1 kinase inhibitor azenosertib. The data was published in abstract format for the European Society for Medical Oncology Congress 2026. In platinum-resistant ovarian cancer patients expressing Cyclin E1 (n=48), median overall survival reached 15.8 months, compared to 7.5 months in negative cohorts. The biomarker stratification establishes clinical differentiation for registrational design.
    → Doubling median overall survival to 15.8 months in the Cyclin E1 biomarker group de-risks regulatory approval paths for WEE1 inhibitor azenosertib, repricing ZNTL equity valuation.
    Impact
    Zentalis presented initial overall survival metrics from the DENALI Part 1b study evaluating its oral WEE1 kinase inhibitor azenosertib. The data was published in abstract format for the European Society for Medical Oncology Congress 2026. In platinum-resistant ovarian cancer patients expressing Cyclin E1 (n=48), median overall survival reached 15.8 months, compared to 7.5 months in negative cohorts. The biomarker stratification establishes clinical differentiation for registrational design.
    Affected
    ZNTL
    Transmission
    Doubling median overall survival to 15.8 months in the Cyclin E1 biomarker group de-risks regulatory approval paths for WEE1 inhibitor azenosertib, repricing ZNTL equity valuation.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZNTLbiomarker clinical survival de-risking registrational trial pathUp1-5dDENALI Part 1b interim OS reached 15.8 months in Cyclin E1-positive patients versus 7.5 months in Cyclin E1-negative patients.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month